High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.

@article{Horning1997HighdoseTA,
  title={High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.},
  author={Sundya J. Horning and Nelson J Chao and Robert S. Negrin and Richard T Hoppe and Gwynn D. Long and Wendy W. Hu and Ruby M. Wong and Barry W. Brown and Ryotaro Nakamura},
  journal={Blood},
  year={1997},
  volume={89 3},
  pages={
          801-13
        }
}
One hundred nineteen patients with relapsed or refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic progenitor cell transplantation. Three preparatory regimens, selected on the basis of prior therapy and pulmonary status, were employed. Twenty-six patients without a history of prior chest or pelvic irradiation were treated with fractionated total body irradiation, etoposide (VP) 60 mg/kg and cyclophosphamide (Cy) 100 mg/kg. Seventy-four patients… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 95 CITATIONS, ESTIMATED 42% COVERAGE

Autologous stem cell transplantation in Hodgkin's disease.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2002
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma.

  • Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • 2002
VIEW 12 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2008
VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
VIEW 5 EXCERPTS
CITES RESULTS, BACKGROUND & METHODS
HIGHLY INFLUENCED

Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2018

FILTER CITATIONS BY YEAR

1997
2018

CITATION STATISTICS

  • 6 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Fractionated total-body irradiation, etoposide, and cyclo12:1021

KG Blume
  • 1994

Bensinger matopoietic rescue for Hodgkin’s disease following first relapse after chemotherapy

T Demirer, CH Weaver, CD Buckner, FB Petersen
  • Proc Am Soc Clin Oncol
  • 1993

Detection of tumor cells in purgeddate

RS Negrin, J Pesando
  • Ann Oncol
  • 1993

Total body irradiaHodgkin ’ s lymphoma : A dosefinding study

GJ Bubley, JM Rappaport, +11 authors IJ Sniecinski
  • Ann Oncol
  • 1993

nancies who have received dose-limiting radiation therapy

PJ Bierman, RG Bagin, S Jagannath, JM Vose, G Spitzer
  • J Clin Kessinger
  • 1993

stem cell transplantation in primary treatment of Hodgkin ’ s disease

AM Carella, DL Darrington, +8 authors Tarantolo
  • J Clin Oncol
  • 1989